A Single-arm, Multicenter, Exploratory Study of Adebrelimab Combined With Apatinib and Systemic Chemotherapy for Initially Unresectable Biliary Tract Cancer

NCT07135544 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

37

Enrollment

OTHER

Sponsor class

Conditions

Biliary Tract Cancer
Biliary Tract Cancer (CCA)

Interventions

DRUG: Adebrelimab combined with the GC regimen and Apatinib

Sponsor

Yongjun Chen